PRANA BIOTECHNOLOGY
PRANA BIOTECHNOLOGY operates in Diversified Metals & Mining.
PRANA BIOTECHNOLOGY (PBN) - Net Assets
Latest net assets as of June 2024: €13.80 Million EUR
Based on the latest financial reports, PRANA BIOTECHNOLOGY (PBN) has net assets worth €13.80 Million EUR as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€19.22 Million) and total liabilities (€5.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €13.80 Million |
| % of Total Assets | 71.78% |
| Annual Growth Rate | -9.76% |
| 5-Year Change | 92.96% |
| 10-Year Change | N/A |
| Growth Volatility | 117.92 |
PRANA BIOTECHNOLOGY - Net Assets Trend (2016–2024)
This chart illustrates how PRANA BIOTECHNOLOGY's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PRANA BIOTECHNOLOGY (2016–2024)
The table below shows the annual net assets of PRANA BIOTECHNOLOGY from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | €13.80 Million | -39.52% |
| 2023-06-30 | €22.81 Million | -35.68% |
| 2022-06-30 | €35.47 Million | +16.40% |
| 2021-06-30 | €30.47 Million | +326.11% |
| 2020-06-30 | €7.15 Million | -56.81% |
| 2019-06-30 | €16.55 Million | +2.95% |
| 2018-06-30 | €16.08 Million | -32.12% |
| 2017-06-30 | €23.69 Million | -24.48% |
| 2016-06-30 | €31.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PRANA BIOTECHNOLOGY's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8928594900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €227.96 Million | 1652.11% |
| Total Equity | €13.80 Million | 100.00% |
PRANA BIOTECHNOLOGY Competitors by Market Cap
The table below lists competitors of PRANA BIOTECHNOLOGY ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CANADA RARE EARTH - Frankfurt Stock Exchang
F:P4XA
|
$50.18 |
|
GALILEO RES PLC LS-001
F:2GA
|
$50.27 |
|
GARUDA INDO -B-
MU:YGD
|
$50.38 |
|
BATR
JK:BATR
|
$50.43 |
|
Philippine Estates Corp
PSE:PHES
|
$49.99 |
|
DIRE CIPTADANA PROPERTI PERHOTELAN PADJAJARAN
JK:XCIS
|
$49.74 |
|
McHenry Metals Golf Corp
OTCGREY:GLFN
|
$49.73 |
|
CeCors Inc
PINK:CEOS
|
$49.69 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PRANA BIOTECHNOLOGY's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 22,812,909 to 13,798,057, a change of -9,014,852 (-39.5%).
- Net loss of 19,123,464 reduced equity.
- New share issuances of 10,144,682 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-19.12 Million | -138.6% |
| Share Issuances | €10.14 Million | +73.52% |
| Other Changes | €-36.07K | -0.26% |
| Total Change | €- | -39.52% |
Book Value vs Market Value Analysis
This analysis compares PRANA BIOTECHNOLOGY's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.90x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.11x to 1.90x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-06-30 | €0.04 | €0.01 | x |
| 2018-06-30 | €0.03 | €0.01 | x |
| 2019-06-30 | €0.02 | €0.01 | x |
| 2020-06-30 | €0.01 | €0.01 | x |
| 2021-06-30 | €0.01 | €0.01 | x |
| 2022-06-30 | €0.01 | €0.01 | x |
| 2023-06-30 | €0.01 | €0.01 | x |
| 2024-06-30 | €0.00 | €0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PRANA BIOTECHNOLOGY utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -138.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.39x
- Recent ROE (-138.60%) is below the historical average (-72.91%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -24.64% | -5418.28% | 0.00x | 1.08x | €-10.87 Million |
| 2017 | -31.84% | -5696.60% | 0.01x | 1.07x | €-9.91 Million |
| 2018 | -51.40% | -4108.75% | 0.01x | 1.16x | €-9.87 Million |
| 2019 | -74.53% | -11367.29% | 0.01x | 1.20x | €-13.99 Million |
| 2020 | -188.19% | 0.00% | 0.00x | 1.39x | €-14.17 Million |
| 2021 | -50.24% | 0.00% | 0.00x | 1.10x | €-18.36 Million |
| 2022 | -36.22% | 0.00% | 0.00x | 1.17x | €-16.39 Million |
| 2023 | -60.52% | 0.00% | 0.00x | 1.20x | €-16.09 Million |
| 2024 | -138.60% | 0.00% | 0.00x | 1.39x | €-20.50 Million |
Industry Comparison
This section compares PRANA BIOTECHNOLOGY's net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $114,212,818,724
- Average return on equity (ROE) among peers: -9.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PRANA BIOTECHNOLOGY (PBN) | €13.80 Million | -24.64% | 0.39x | $50.10 |
| HORIBA (01H) | $204.49 Billion | 10.42% | 0.82x | $989.01K |
| Tokyu Corporation (01T) | $779.37 Billion | 3.34% | 2.35x | $99.73K |
| GUANGZHOU AUTO -H- (02G) | $122.28 Billion | 6.59% | 0.55x | $4.05K |
| MOSAIC (02M) | $10.60 Billion | 4.43% | 0.90x | $280.83K |
| MOSAIC (02M.SG) (02M) | $9.56 Billion | 10.46% | 0.82x | $247.21K |
| CHINA JO-JO DRGSTRS (04CN.SG) (04CN) | $16.67 Million | -126.83% | 4.46x | $1.55 Million |
| KRAKATAU STEEL -B- (07K) | $552.59 Million | 3.52% | 4.72x | $166.99 |
| CN MODERN DAIRY (07M) | $7.12 Billion | -10.42% | 1.50x | $1.68K |
| TOURMALINE OIL (08T) | $7.22 Billion | 4.81% | 0.41x | $381.02K |
| ASIA CASSAVA RESOUR (0ACS) | $913.15 Million | 2.86% | 1.55x | $325.03 |